In the pipeline: Trastuzumab-DM1 active after HER2 therapy fails - Commentary

William J. Gradishar

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'In the pipeline: Trastuzumab-DM1 active after HER2 therapy fails - Commentary'. Together they form a unique fingerprint.